2026-01-07 - Analysis Report
Okay, let's break down the analysis of Merck & Co. (MRK).

**0. Report Preparation**

Report generated in English. Simple numbers are presented first, followed by analysis.

**1. Return Rate Comparison (MRK vs. S&P 500)**

*   **Company Overview:** Merck & Co. Inc. is a global pharmaceutical company that develops and markets a wide range of healthcare products.
*   **MRK Cumulative Return:** 22.93%
*   **VOO (S&P 500) Cumulative Return:** 91.00%
*   **Divergence:** -68.07 (Relative Divergence: 23.8)

**Analysis:**

MRK has significantly underperformed the S&P 500 over the analyzed period. The negative divergence of -68.07 indicates a substantial difference in cumulative returns. The relative divergence of 23.8 suggests that this underperformance is closer to the minimum divergence observed historically for this comparison.

**Alpha, Beta Analysis Table:**

| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2016-2018  | 24.0% | 14.7% | 21.0% | 0.7 | 186.2 |
| 2017-2019  | 37.0% | 14.7% | 20.0% | 0.7 | 221.7 |
| 2018-2020  | 13.0% | 19.3% | -8.0% | 0.7 | 199.4 |
| 2019-2021  | 0.0% | 19.3% | -43.0% | 0.6 | 195.8 |
| 2020-2022  | 14.0% | 16.3% | 16.0% | 0.5 | 283.4 |
| 2021-2023  | 31.0% | 14.3% | 30.0% | 0.3 | 278.5 |
| 2022-2024  | -5.0% | 24.9% | -24.0% | 0.3 | 254.1 |
| 2023-2025  | -24.0% | 39.0% | -86.0% | 0.3 | 268.9 |

**Analysis:**

*   **Alpha:** Alpha measures the stock's risk-adjusted performance relative to the S&P 500.  The negative alpha values in recent periods (2018-2020, 2019-2021, 2022-2024, 2023-2025) indicate underperformance compared to the S&P 500 during those times.
*   **Beta:** Beta measures the stock's volatility relative to the S&P 500. A beta consistently below 1 (ranging from 0.3 to 0.7) suggests that MRK is less volatile than the overall market. The decreasing trend in Beta suggests that the stock's correlation with the market has been weakening.
*   **CAGR:**  The Compound Annual Growth Rate (CAGR) shows inconsistent growth. Recent periods (2022-2024, 2023-2025) show negative growth.
*   **MDD:** The Maximum Drawdown (MDD) indicates the largest peak-to-trough decline during the period. MDD is increasing, reaching 39% (2023-2025).
*   **Cap:** Market Capitalization is high and seems to be consistently high.

**2. Recent Stock Price Fluctuations**

*   **Current Close:** 106.45
*   **Last Market Data:** {'price': 108.87, 'previousClose': 107.44, 'change': 1.33}
*   **5-day SMA:** 106.23
*   **20-day SMA:** 102.01
*   **60-day SMA:** 94.48

**Analysis:**

*   The price is currently above all its moving averages, indicating an upward trend in the short, medium, and long term.
*   The 5-day SMA is above the 20-day SMA, which is above the 60-day SMA, reinforcing this bullish signal.
*   The last market data shows a positive change, suggesting continued upward momentum in the very short term.

**3. RSI, PPO, and Market Risk Indicators**

*   **MRI:** 0.8 (Medium Investment Recommended)
*   **RSI:** 75.58
*   **PPO:** 0.0841
*   **Hybrid Signal:** cash_0%_Buy 90% of cash (8 shares - Safe - MRI:0.80) Monthly invest 0.8% of total investment ($1,000.00) (Cash Ratio: 0% on 2026-01-02)
*   **Recent Divergence Change:** 2.0 (+) (단기상승 - short-term increase)
*   **Expected Return (%):** -27.3 (Expected excess return compared to S&P 500 if invested long-term (more than 2 years) from this point.)

**Analysis:**

*   **MRI:** A Market Risk Indicator of 0.8 suggests a medium investment recommendation.
*   **RSI:** The RSI is at 75.58, which is in the overbought territory (typically above 70). This suggests that the stock might be due for a correction or consolidation.
*   **PPO:** The PPO is positive (0.0841), indicating that the shorter-term moving average is above the longer-term moving average, confirming the upward trend.
*   **Hybrid Signal:** The signal suggests a buy recommendation, allocating 90% of cash and a monthly investment. The cash ratio is 0%, indicating a fully invested strategy.
*   **Recent Divergence Change:**  A positive divergence change indicates a recent short-term increase.
*   **Expected Return:** The negative expected return (-27.3%) is a major concern. It suggests that, based on current conditions, long-term investment in MRK is expected to underperform the S&P 500.

**4. Recent News & Significant Events (Yahoo Finance)**

*   **2026-01-06:** CDC vaccine overhaul and Gardasil dosing in the spotlight.
*   **2026-01-06:** Merck gains despite CDC HPV dosing shift.
*   **2026-01-06:** Spirepoint Private Client LLC sold shares of Merck.
*   **2025-12-16:** Morgan Stanley lifts Merck's price target due to an improving biopharma outlook.
*   **2025-12-24:** Questioning the legitimacy of Merck's stock run.
*   **2026-01-05:** Merck stock hits a 52-week high.

**Analysis:**

The news is mixed. The headlines about the CDC vaccine overhaul and Gardasil dosing create uncertainty.  The news about Spirepoint selling shares could create downward pressure. However, Morgan Stanley's price target increase and the 52-week high are positive signals. Overall, the news suggests a period of volatility and potential re-evaluation of the stock.

**4-2) Analyst Opinions**

*   **Consensus:** Buy (Mean: 1.90)
*   **Target Price:** Average: 110.04, High: 139.00, Low: 83.00

**Analysis:**

Despite the mixed news and some concerning indicators, the analyst consensus remains a "Buy," with an average price target slightly above the current price. The high target price suggests some analysts are very optimistic. However, the low target price indicates significant disagreement among analysts.

**5. Recent Earnings Analysis**

| 날짜        | EPS   | 매출        |
| ----------- | ----- | ----------- |
| 2025-11-05  | 2.32  | 17.28 B$    |
| 2025-08-05  | 1.76  | 15.81 B$    |
| 2025-05-02  | 2.01  | 15.53 B$    |
| 2024-11-06  | 1.25  | 16.66 B$    |
| 2025-11-05  | 1.25  | 16.66 B$    |

**Analysis:**

*   **EPS:** Earnings per share (EPS) is volatile but showing an upward trend. The latest EPS is significantly higher than the EPS from a year ago.
*   **Revenue:** Revenue also showing an upward trend.
*   The increased earnings and revenue may justify the stock hitting a 52-week high.

**6. Financial Information**

**Revenue and Profitability:**

| Quarter      | Revenue    | Profit Margin |
| ----------- | ---------- | --------------- |
| 2025-09-30  | $17.28B   | 77.69%          |
| 2025-06-30  | $15.81B   | 77.50%          |
| 2025-03-31  | $15.53B   | 77.98%          |
| 2024-12-31  | $15.62B   | 75.50%          |
| 2024-09-30  | $16.66B   | 75.51%          |

**Capital and Profitability:**

| Quarter      | Equity      | ROE   |
| ----------- | ----------- | ----- |
| 2025-09-30  | $51.85B    | 11.16% |
| 2025-06-30  | $48.99B    | 9.04%  |
| 2025-03-31  | $48.34B    | 10.51% |
| 2024-12-31  | $46.31B    | 8.08%  |
| 2024-09-30  | $44.50B    | 7.09%  |

**Analysis:**

*   **Revenue:** Consistent revenue growth over the past five quarters.
*   **Profit Margin:** High and stable profit margins, consistently above 75%. This indicates strong pricing power and efficient cost management.
*   **Equity:** Growing equity base, reflecting retained earnings and overall financial health.
*   **ROE:** Return on Equity (ROE) is improving, suggesting increasing profitability relative to shareholders' equity.

**7. Comprehensive Analysis (Summary)**

Merck (MRK) presents a mixed investment picture. While recent performance has significantly lagged the S&P 500, with negative Alpha and a substantial divergence in cumulative returns, there are also positive signals.

**Positive Signals:**

*   **Recent Price Momentum:** The stock is trading above its moving averages, showing short-term upward momentum.
*   **Analyst Consensus:** The consensus rating is "Buy," suggesting continued optimism.
*   **Strong Financials:** Revenue and profit margins are high and stable, equity is growing, and ROE is improving. Recent earning results are also positive.
*   **Medium Investment Recommendation:** MRI supports medium investment.

**Negative Signals:**

*   **Underperformance:** Significant underperformance relative to the S&P 500.
*   **Negative Expected Return:** Concerning negative long-term expected return compared to the S&P 500.
*   **RSI Overbought:** The RSI indicates the stock may be overbought and due for a correction.
*   **News Uncertainty:** Recent news regarding CDC vaccine policies and share sales introduces uncertainty.

**Overall Assessment:**

The key concern is the substantial underperformance and negative expected return compared to the S&P 500. While recent price momentum and strong financials are encouraging, the negative signals cannot be ignored. The overbought RSI and mixed news suggest caution.

**Recommendation:**

A cautious approach is warranted. Consider the analyst opinions, but factor in the recent news and the negative expected return.

*   **If already holding MRK:** Consider holding.
*   **If considering a new position:** Wait for a pullback or consolidation to reduce risk.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.